key: cord-0282441-cbo977lu
authors: Patel, Nikita M; Oliveira, Filipe RMB; Ramos, Hanna Pillmann; Aimaretti, Eleonora; Alves, Gustavo Ferreira; Coldewey, Sina M; Collino, Massimo; Sordi, Regina; Thiemermann, Christoph
title: Inhibition of Bruton’s tyrosine kinase activity attenuates trauma-induced multiple organ dysfunction in rats
date: 2021-09-24
journal: bioRxiv
DOI: 10.1101/2021.09.23.460775
sha: a6b9e8dbf85f1414e28e40784a2247370865f86c
doc_id: 282441
cord_uid: cbo977lu

Objective The aim of this study was to investigate (a) the potential of the Bruton’s tyrosine kinase (BTK) inhibitors (BTKi) acalabrutinib and fenebrutinib to reduce multiple organ dysfunction syndrome (MODS) in acute and chronic hemorrhagic shock (HS) rat models and (b) whether treatment with either acalabrutinib or fenebrutinib attenuates BTK, NF-κB and NLRP3 activation in HS. Background The MODS caused by an excessive systemic inflammatory response following trauma is associated with a high morbidity and mortality. The protein BTK is known to play a role in the activation of the NLRP3 inflammasome, which is a key component of the innate inflammatory response. However, its role in trauma-hemorrhage is unknown. Methods Acute and chronic HS rat models were performed to determine the influence of acalabrutinib or fenebrutinib on MODS. The activation of BTK, NF-κB and NLRP3 pathways were analyzed by western blot in the kidney. Results We demonstrated that (a) HS caused organ injury and/or dysfunction and hypotension (post resuscitation) in rats, while (b) treatment of HS-rats with either acalabrutinib or fenebrutinib attenuated the organ injury and dysfunction in acute and chronic HS models and (c) reduced the activation of BTK, NF-κB and NLRP3 pathways in the kidney. Conclusion Our results point to a role of BTK in the pathophysiology of organ injury and dysfunction caused by trauma/hemorrhage and indicate that BTK inhibitors may be repurposed as a potential therapeutic approach for MODS after trauma and/or hemorrhage. MINI-ABSTRACT This study evaluated the role of Bruton’s tyrosine kinase (BTK) in trauma/hemorrhage. Patients with trauma had elevated gene expression of BTK. The BTK inhibitors acalabrutinib (irreversible) and fenebrutinib (reversible) attenuated the trauma-induced multiple organ dysfunction in rats with hemorrhagic shock, indicating that BTK could be a potential therapeutic target.

Bruton's tyrosine kinase (BTK) is a cytoplasmic, non-receptor protein tyrosine kinase belonging to the Tec family of kinases and was first discovered in X-linked agammaglobulinemia 5 . All cells of hematopoietic origin except plasma cells, natural killer cells

and T-lymphocytes express BTK 6 . Whilst BTK was initially known for its critical role in Blymphocyte development and, thus, adaptive immunity, more recent studies point to a pivotal role for BTK in innate immunity 7 .

It is known that trauma leads to a so-called 'genomic storm' that results in a change in >80% of cellular functions and pathways 8 . Specifically, there is an increased expression in genes related to systemic inflammatory and innate immune responses. Of particular interest was the observation that B-lymphocyte receptor signaling was one of the most upregulated pathways. 6 We have recently discovered that inhibition of BTK activity with either ibrutinib or acalabrutinib reduces the multiple organ (cardiac, renal, hepatic) injury/dysfunction caused by cecum-ligation and puncture (CLP)-sepsis in the mouse. Moreover, the BTKi used reduced the activation of NF-κB and the NLRP3 inflammasome as well as the release of many proinflammatory cytokines and chemokines triggered by CLP-sepsis 9 . Most notably, X-Linked immunodeficient mice with inactive BTK function were also protected from sepsis-induced MODS 10 . Furthermore, prevention of NF-κB activation reduces the onset of multiple organ injury and improves the survival rate in rodent models of septic shock 11 

Original data was obtained under Gene Expression Omnibus (GEO) accession GSE36809, published by Xiao and colleagues 8 . RNA was extracted from whole blood leukocytes of severe blunt trauma patients (n = 167) over the course of 28 days and healthy controls (n = 37) and

hybridized onto an HU133 Plus 2.0 GeneChip (Affymetrix) according to the manufacturer's recommendations. The dataset was reanalyzed for BTK gene expression in these two groups.

For the acute HS model, all animal procedures were approved by the Animal Welfare Ethics and rats were treated (i.v. in acute and i.p. in chronic model) upon resuscitation.

The acute hemorrhagic shock model was performed as previously described [19] [20] [21] . Briefly, fiftyfour rats were anesthetized with sodium thiopentone (120 mg/kg i.p. initially and 10 mg/kg i.v.

for maintenance as needed) and randomized into six groups: Sham + vehicle (n = 9); Sham + Figure 1A) .

Thirty-eight rats were administered analgesia with tramadol (10 mg/kg i.p.) 15 min prior to anesthesia induction with ketamine and xylazine (100 mg/kg and 10 mg/kg i.m. respectively) and randomized into four groups: Sham + vehicle (n = 9); Sham + acalabrutinib (3 mg/kg; n = 10); HS + vehicle (n = 10); HS + acalabrutinib (3 mg/kg; n = 9). Blood was withdrawn to achieve a fall in MAP to 40 ± 2 mmHg, which was maintained for 90 min. At 90 min after initiation of hemorrhage (or when 25% of the shed blood had to be reinjected to sustain MAP), resuscitation was performed with the shed blood over a period of 5 mins plus 1.5 mL/kg Ringer's lactate. At 24 h post-resuscitation, blood was collected for the measurement of organ injury parameters (Hospital Universitário Professor Polydoro Ernani de São Thiago, Brazil).

Sham-operated rats were used as control and underwent identical surgical procedures, but without hemorrhage or resuscitation. Detailed description can be found in the supplemental section (Supplemental Figure 1B) .

Semi-quantitative immunoblot analysis was carried out in kidney tissue samples as previously described 22 . The following antibodies were used: rabbit anti-total BTK, rabbit anti-NF-κB, rabbit anti-total IKKα/β, rabbit anti-Ser 176/180 IKKα/β, mouse anti-Ser 32/36 IκBα, mouse antitotal IκBα, (from Cell Signaling), rabbit anti-Tyr 223 -BTK, rabbit anti-NLRP3 inflammasome (from Abcam) and mouse anti-caspase 1 (p20) (from Adipogen). Detailed description of the method can be found in the supplemental section.

Lung and liver tissue samples from the chronic HS model were homogenized in liquid nitrogen with a pestle and mortar. The homogenate was then centrifuged at 13,000 x g at 4 °C for 10 min and the supernatant was assayed for myeloperoxidase (MPO) activity by measuring the H2O2-dependent oxidation of 3,3,5,5-tetramethylbenzidine (TMB). MPO activity was determined colorimetrically using an ultra-microplate reader (EL 808, BioTek Instruments, 

Xiao and colleagues 8 isolated whole blood leukocytes, extracted the total cellular RNA and We reanalyzed this dataset for BTK expression in these groups. When compared to healthy controls, BTK expression was significantly elevated at all time points except 12 h (p<0.05; Figure 1 ). An initial peak was noted at Day 1 followed by a gradual decrease, however, BTK expression remained elevated at Day 28.

To investigate the effects of the BTK inhibitors (BTKi) acalabrutinib and fenebrutinib on circulatory failure, MAP was measured from the completion of surgery to the termination of the experiment. Baseline MAP values were similar amongst all six groups. Rats subjected to HS demonstrated a decline in MAP which was ameliorated by resuscitation, but MAP remained lower than that of sham-operated rats during resuscitation (at the equivalent time points, Figure   2A ). When compared to sham-operated rats, HS-rats treated with vehicle exhibited a more pronounced decrease in MAP over time post resuscitation. The MAP of HS-rats treated with either acalabrutinib or fenebrutinib was significantly higher than that of HS-rats treated with vehicle at the end of the resuscitation period (p<0.05; Figure 2B ). No significant differences were observed between HS-rats treated with either acalabrutinib or fenebrutinib (p>0.05; Figure 2A ). Administration of acalabrutinib or fenebrutinib to sham-operated rats had no significant effect on MAP (p>0.05; Figure 2A ).

Here we explored whether pharmacological intervention with the BTKi acalabrutinib and fenebrutinib attenuates the MODS associated with HS in rats. When compared to shamoperated rats, rats subjected to HS and treated with vehicle displayed increases in serum urea (p<0.05; Figure 3A ) and creatinine (p<0.05; Figure 3B ); indicating the development of renal dysfunction. When compared to sham-operated rats, vehicle treated HS-rats exhibited significant increases in ALT (p<0.05; Figure 3C ) and AST (p<0.05; Figure 3D ) indicating the development of hepatic injury, while the increases in CK (p<0.05; Figure 3E ) and amylase shown). No significant differences were observed between HS-rats treated with either acalabrutinib or fenebrutinib (p>0.05; Figure 3 ). Administration of either BTKi to shamoperated rats had no significant effect on any of the parameters measured (p>0.05; Figure 3 ).

Using western blot analysis, we examined whether HS leads to the activation of BTK in the kidney; given that treatment with either BTKi significantly attenuated HS-associated renal dysfunction. The activation of BTK and subsequent BTK-associated signaling pathways

consists of the phosphorylation of BTK at Tyr 223 as the initial stage of the BTK-signaling cascade. When compared to sham-operated rats, HS-rats treated with vehicle displayed significant increases in the phosphorylation of BTK at Tyr 223 , indicating that BTK is activated in injured kidneys (p<0.05; Figure 4A ). Treatment with BTKi in HS-rats significantly abolished the increases in the phosphorylation of BTK at Tyr 223 (p<0.05; Figure 4A ). No significant differences were observed in the degree of phosphorylation (in the kidney) of BTK at Tyr 223 between HS-rats treated with either acalabrutinib or fenebrutinib (p>0.05; Figure 4A ).

These data demonstrate that both BTKi abolish the activation of BTK caused by HS.

The effect of BTK inhibition on the activation of the signaling events leading to the activation of NF-κB, were investigated in the kidney. When compared to sham-operated rats, HS-rats treated with vehicle had significant increases in the phosphorylation of IKKα/β at Ser 176/180 (p<0.05; Figure 4B ), phosphorylation of IκBα at Ser 32/36 (p<0.05; Figure 4C ) and the translocation of p65 to the nucleus (p<0.05; Figure 4D ). Treatment of HS-rats with either BTKi significantly abolished the increase in renal phosphorylation of IKKα/β at Ser 176/180 (p<0.05; Figure 4B ), the phosphorylation of IκBα at Ser 32/36 (p<0.05; Figure 4C ) and the nuclear translocation of p65 (p<0.05; Figure 4D ). No significant differences were observed in the degree of phosphorylation of IKKα/β at Ser 176/180 , phosphorylation of IκBα at Ser 32/36 and the translocation of p65 to the nucleus between HS-rats treated with either acalabrutinib or fenebrutinib (p>0.05; Figures 4B-D) . These data illustrate that both BTKi abolish the activation of NF-κB caused by HS.

Having discovered that BTKi significantly reduced the activation of NF-κB in the kidney of rats subjected to HS, we next analyzed the potential involvement of the NLRP3 inflammasome complex. When compared to sham-operated rats, HS-rats treated with vehicle exhibited a significantly increased expression of the NLRP3 inflammasome (p<0.05; Figure 4E ) and of the cleaved (activated) form of caspase 1 (p<0.05; Figure 4F ). Treatment of HS-rats with either

BTKi acalabrutinib or fenebrutinib significantly inhibited the renal expression of NLRP3 (p<0.05; Figure 4E ) and cleaved form of caspase 1 (p<0.05; Figure 4F ). No significant differences were observed in the degree of expression of the NLRP3 inflammasome and cleaved form of caspase 1 between HS-rats treated with either acalabrutinib or fenebrutinib (p>0.05; Figures 4E-F) . These data demonstrate that both BTKi abolish the activation of the NLRP3 inflammasome and caspase 1 and the subsequent formation of IL-1β.

Firstly, to address the question whether the degree of activation of BTK correlates with changes in renal function, we correlated the degree of phosphorylation of BTK at Tyr 223 with serum creatinine ( Figure 5A ), urine creatinine ( Figure 5B ) and serum urea ( Figure 5C ). We found a highly significant positive correlation between the degree of BTK activation and the increases in serum creatinine ( Figure 5A ) and urea ( Figure 5C ), suggesting that BTK activation drives or precedes the renal dysfunction associated with hemorrhagic shock. No significant correlation was observed between BTK activation and the decrease in urine creatinine ( Figure   5B ). Secondly, the potential relationship between the degree of activation of BTK and alterations in the activation of NF-κB was also addressed by correlating the degree of phosphorylation of BTK at Tyr 223 with the phosphorylation of IKKα/β at Ser 176/180 (Figure 5D ), the phosphorylation of IκBα at Ser 32/36 ( Figure 5E ) and the translocation of p65 ( Figure 5F ).

We found a highly significant positive correlation between the degree of BTK activation and NF-κB activation when measured as IKKα/β phosphorylation at Ser 176/180 ( Figure 5D ), IκBα phosphorylation at Ser 32/36 ( Figure 5E ) and p65 translocation ( Figure 5F ). Thirdly, whether the degree of activation of BTK correlates with changes in the assembly and activation of the NLRP3 inflammasome was investigated by correlating the degree of phosphorylation of BTK at Tyr 223 with the expression of NLRP3 ( Figure 5G ) and the cleaved (activated) form of caspase 1 ( Figure 5H ). We found a highly significant positive correlation between the degree of BTK activation and the NLRP3 inflammasome expression ( Figure 5G ) and the activation of caspase 1 ( Figure 5H ).

When comparing acalabrutinib and fenebrutinib, both inhibitors were equally efficacious in the acute HS model but acalabrutinib has the advantage of being FDA approved; hence was investigated in a chronic HS model. Having demonstrated treatment with acalabrutinib improved blood pressure in an acute HS rat model, we wished to determine whether acalabrutinib would still be effective in a HS model in which the resuscitation period is prolonged to 24 h. When compared to sham-operated rats, HS-rats treated with vehicle had significantly lower values of MAP recorded 24 h after the onset of resuscitation (p<0.05; Figure   6A ); highlighting that either cardiac dysfunction or excessive hypotension 23 was still present.

In contrast, the MAP values of HS-rats treated with acalabrutinib upon resuscitation were significantly higher even at 24 h after the onset of resuscitation [when compared with those of vehicle treated rats (p<0.05; Figure 6A) ]. Administration of acalabrutinib to sham-operated rats had no significant effect on MAP (p>0.05; Figure 6A ). There were no significant differences in HR between any of the four groups investigated (p>0.05; Figure 6B ).

Having shown that treatment with acalabrutinib ameliorated the MODS associated with HS in an acute HS rat model, we examined whether this effect was sustained when the resuscitation period was extended to 24 h. As with the acute HS model, when compared to sham-operated rats, rats subjected to chronic HS and treated with vehicle displayed significant increases in serum urea (p<0.05; Figure 7A ) and creatinine (p<0.05; Figure 7B ); indicating the development of renal dysfunction. When compared to sham-operated rats, vehicle treated HSrats exhibited significant increases in ALT (p<0.05; Figure 7C ) and AST (p<0.05; Figure 7D) indicating the development of hepatic injury, whilst the significant increase in LDH (p<0.05; 

We next determined myeloperoxidase (MPO) activity in the lung and liver of rats subjected to HS as an indicator of neutrophil infiltration. When compared to sham-operated rats, HS-rats treated with vehicle showed a significant increase in MPO activity in the lung (p<0.05; Figure   7F ) and liver (p<0.05; Figure 7G ). Treatment with acalabrutinib in HS-rats significantly attenuated the rises in pulmonary ( Figure 7F ) and hepatic ( Figure 7G ) MPO activity (p<0.05), suggesting reduced neutrophil recruitment and inflammation. Administration of acalabrutinib to sham-operated rats had no significant effect on both pulmonary and hepatic MPO activity (p>0.05; Figures 7F-G) .

This study reports for the first time that inhibition of BTK activity attenuates organ injury/dysfunction and circulatory failure in acute (Figures 2 and 3) and chronic (Figures 6 and   7 ) rat models of HS. Having shown that BTK gene expression is significantly elevated in leukocytes of trauma patients (Figure 1 There is good evidence that BTK activation precedes the activation of NF-κB through TLR signaling 32 . Indeed, trauma results in elevated NF-κB translocation to the nucleus [19] [20] [21] [22] .

Inhibition of BTK activity with acalabrutinib or fenebrutinib reduced the activation of NF-κB in the kidney (Figure 4) . We also found a significant positive correlation between the activation of BTK and the phosphorylation of IKKα/β at Ser 176/180 , phosphorylation of IκBα at Ser 32/36

and translocation of p65 ( Figure 5 ). This may suggest that inhibiting the activation of NF-κB contributes to the observed beneficial effects of acalabrutinib and fenebrutinib in traumahemorrhage; as NF-κB activation is involved in the regulation of immunological and inflammatory responses. Activation of NF-κB drives the formation of several pro-and antiinflammatory mediators which include cytokines, chemokines and enzymes 33 . As part of a positive feedback loop, these mediators can activate NF-κB and its upstream signaling components, further amplifying and perpetuating the inflammatory responses mediated by NF-κB which can lead to increased endothelial permeability, tissue hypoperfusion/hypoxia, tissue injury and ultimately MODS 11 . It should be noted that the inhibition of BTK activity in CLPsepsis also reduced activation of NF-κB 9 .

There is also good evidence that BTK activation influences the assembly and activation of the NLRP3 inflammasome in rodents and humans [34] [35] [36] . NLRP3 inflammasome activation drives the production of IL-1β which plays a crucial role in the systemic inflammation and/or organ dysfunction in trauma 22 . Inhibition of BTK activity with acalabrutinib or fenebrutinib reduces both the assembly and subsequent activation of the NLRP3 inflammasome in the kidney ( Figure 4) . We also discovered a significant positive correlation between the activation of BTK 20 and both the activation of NLRP3 and caspase 1 ( Figure 5 ). This may suggest that inhibiting the activation of the NLRP3 inflammasome contributes to the observed protective effects of acalabrutinib and fenebrutinib in trauma-hemorrhage by lowering the pro-inflammatory effects of IL-1β and resulting tissue inflammation. This is due to IL-1β not only directly causing inflammation but also stimulating the expression of several pro-inflammatory adhesion molecules and cytokines which further exacerbates the inflammatory response 37 . It should be noted that the inhibition of BTK activity in CLP-sepsis also reduced activation of NLRP3 and cleavage of pro-caspase 1 to caspase 1 9 . highlighting the potential for BTK to be a predictor of mortality 10 .

Although acalabrutinib and fenebrutinib displayed some striking, beneficial effects in the HS models, there are study limitations which should be considered. Further long-term survival experiments are needed to verify that the observed early reduction in MODS does, indeed, translate to improved outcome and ultimately reduced mortality. In our study, organ injury and dysfunction were used as surrogate markers for mortality (as the determination of mortality is not allowed by our respective ethics and/or Home Office licenses). Therefore, care must be taken when interpreting our pre-clinical results and extrapolating them to the clinical scenario.

In addition, future studies in larger animals and/or higher species may be useful to confirm efficacy and to further investigate the mechanism of action (e.g. blood gas analysis and microcirculatory effects) of BTKi in HS. As BTK is primarily expressed in cells of

that the increase in BTK activity measured in the kidneys of rats with HS was secondary to the infiltration of these organs by invading immune cells rather than an increase in parenchymal renal tissue (where no expression of BTK has been reported). Therefore, it is possible that inhibition of BTK leads to decreased recruitment of leukocytes into the kidney (as a result of reduced NF-κB and NLRP3 activation) and subsequently to lower levels of BTK activation in the kidney. Furthermore, clinical studies with large cohorts of trauma patients are needed to robustly examine the relationship between BTK activity and clinical outcomes in humans.

In conclusion, we report here for the first time that treatment with either the irreversible BTKi Statistical analysis was performed using one-way ANOVA followed by a Bonferroni's posthoc test. *p<0.05 denoted statistical significance. 

Supplemental digital content: BTK in Trauma Supplemental.pdf

Injuries and Violence: The Facts

The acute management of trauma hemorrhage: A systematic review of randomized controlled trials

Postinjury multiple organ failure

The systemic immune response to trauma: An overview of pathophysiology and treatment. The Lancet

The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases

Bruton's tyrosine kinase (Btk): Function, regulation, and transformation with special emphasis on the PH domain

Bruton's tyrosine kinase: An emerging key player in innate immunity

A genomic storm in critically injured humans

Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice

X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure

NF-κB activation as a pathological mechanism of septic shock and inflammation

Inhibition of IκB kinase reduces the multiple organ dysfunction caused by sepsis in the mouse

Inhibition of IκB kinase attenuates the organ injury and dysfunction associated with hemorrhagic shock

A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover

Tyrosine Kinase Inhibitors: Present and Future

Inhibition of BTK protects lungs from traumahemorrhagic shock-induced injury in rats

Resolvin D1 Attenuates the Organ Injury Associated With Experimental Hemorrhagic Shock

Artesunate protects against the organ injury and dysfunction induced by severe hemorrhage and resuscitation. Annals of Surgery

Novel Synthetic, Host-defense Peptide Protects Against Organ Injury/Dysfunction in a Rat Model of Severe Hemorrhagic Shock

The inhibition of Macrophage Migration Inhibitory Factor by ISO-1 attenuates trauma-induced multi organ dysfunction in rats. medRxiv

Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxide

Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton's Tyrosine Kinase

BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis

Bruton Tyrosine Kinase Inhibition Attenuates Liver Damage in a Mouse Warm Ischemia and Reperfusion Model

Silencing bruton's tyrosine kinase in alveolar neutrophils protects mice from LPS/immune complex-induced acute lung injury

Knockdown of Burton's tyrosine kinase confers potent protection against sepsis-induced acute lung injury. Cell biochemistry and biophysics

Inhibiting bruton's tyrosine kinase rescues mice from lethal influenza-induced acute lung injury

Enhanced Bruton's tyrosine kinase activity in the kidney of patients with IgA nephropathy

Bruton's tyrosine kinase regulates macrophage-induced inflammation in the diabetic kidney via NLRP3 inflammasome 27 activation

Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor κB activation by tolllike receptor 4

The IKK/NF-kappa B pathway

Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury

Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase

BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity. bioRxiv

Biologic basis for interleukin-1 in disease

Transcriptional regulation of endothelial cell adhesion molecules: A dominant role for NF-κB

Transcriptional regulation of endothelial cell adhesion molecules: NF-κB and cytokine-inducible enhancers

Hepatic Nuclear Factor κB Regulates Neutrophil Recruitment to the Injured Brain

NF-κB in immunobiology

Postinjury neutrophil priming and activation: An early vulnerable window

Neutrophil priming and activation in the pathogenesis of postinjury multiple organ failure

Postinjury Inflammation and Organ Dysfunction

The effect of intestinal ischemia and reperfusion injury on ICAM-1 expression, endothelial barrier function, neutrophil tissue influx, and protease inhibitor levels in rats

Delayed neutralization of interleukin 6 reduces organ injury, selectively suppresses inflammatory mediator, and partially normalizes immune dysfunction following trauma and hemorrhagic shock

Identifying key regulatory genes in the whole blood of septic patients to monitor underlying immune dysfunctions